By performing one of the largest studies of the genetic make-up of bone cancers called osteosarcomas, researchers at the Wellcome Trust Sanger Institute and their collaborators discovered that a subset of people with these cancers have genetic mutations that may make their tumours sensitive to an existing drug. Learn more in this article.
Trending Topics:
